The White House dropped Dr. Heidi Overton's nomination to serve as commissioner of the Food and Drug Administration on Tuesday evening. A senior administration official said the move came because Overton lacked the support needed on Capitol Hill to advance her confirmation.

Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated by President Trump in August. She had been scheduled for a vote Wednesday before the Senate Health, Education, Labor and Pensions Committee.

Republican Sen. Bill Cassidy of Louisiana, who chairs the committee, had voiced strong concerns about Overton's role in efforts to alter childhood vaccine recommendations. He described those changes as almost disqualifying and also cited her limited managerial experience.

The nomination drew additional skepticism from some Republican senators over issues including vaping policy and abortion-related stances. Segments of the Make America Healthy Again movement led by Health and Human Services Secretary Robert F. Kennedy Jr. also raised criticisms, viewing Overton as insufficiently aligned with their priorities.

The decision leaves the Trump administration seeking a new candidate to lead the FDA at a time when the agency continues to face staffing challenges and debates over regulatory direction. Overton had been positioned as an ally capable of advancing the president's health agenda, including faster cures and lower drug prices.